{"id":1419,"date":"2026-11-20T07:04:01","date_gmt":"2026-11-20T05:04:01","guid":{"rendered":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/"},"modified":"2026-11-20T07:04:17","modified_gmt":"2026-11-20T05:04:17","slug":"informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/","title":{"rendered":"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>Not every new marketing authorisation needs a new dossier. Under Article 10c of Directive 2001\/83\/EC, a company can obtain its own authorisation for a medicine that is already approved, relying entirely on the original holder&#8217;s data with that holder&#8217;s written consent. For co-marketing partnerships, second brands and licensing deals in Greece and across the EU, the informed consent route is often the fastest and most economical path to market, but it creates an independent authorisation with independent obligations.<\/strong><\/p>\n\n<h2>What Article 10c allows<\/h2>\n<p>An informed consent application is made for a medicinal product with the same qualitative and quantitative composition in active substances and the same pharmaceutical form as a product that is already authorised. Instead of compiling its own quality, non-clinical and clinical modules, the applicant relies on the reference product&#8217;s dossier, supported by a letter of consent from the existing marketing authorisation holder (MAH) covering the pharmaceutical, preclinical and clinical documentation.<\/p>\n<p>The applicant still provides complete administrative data in Module 1, and the new authorisation stands on its own legal basis. The original and the new product may have the same or different MAHs, and they typically carry different invented names.<\/p>\n\n<h2>Duplicates in the centralised procedure<\/h2>\n<p>For centrally authorised products the position is stricter. Article 82(1) of Regulation (EC) No 726\/2004 provides that only one authorisation may be granted to an applicant for a specific medicinal product. The European Commission may allow the same applicant to submit more than one application where there are objective, verifiable reasons relating to public health and the availability of medicines, or for co-marketing reasons.<\/p>\n<ul>\n<li>The applicant must notify the Commission and justify the request before submission to EMA.<\/li>\n<li>The Commission&#8217;s response forms part of the application and is a prerequisite for validation.<\/li>\n<li>Once permitted, duplicates can be submitted as stand-alone or informed consent applications.<\/li>\n<\/ul>\n<p>Where a different company wants its own centralised authorisation for the same product, it relies on informed consent from the MAH rather than the Article 82 duplicate rule.<\/p>\n\n<h2>National, MRP and DCP routes<\/h2>\n<p>For nationally authorised products, informed consent applications can be submitted nationally or through the mutual recognition and decentralised procedures. Timelines and administrative requirements vary between competent authorities, so the procedural strategy, including the choice of Reference Member State and the handling of product names across countries, should be agreed with the partner before filing. In Greece, applications are submitted to EOF, and Greek-specific Module 1 elements such as labelling and pricing data still need to be prepared locally.<\/p>\n\n<h2>Life after approval: two authorisations, two sets of obligations<\/h2>\n<p>The most common misunderstanding is that an informed consent product simply &#8220;follows&#8221; the original. Legally, the new MAH holds a separate authorisation and carries the full responsibilities that come with it:<\/p>\n<ul>\n<li><strong>Pharmacovigilance:<\/strong> its own pharmacovigilance system, QPPV arrangements, ICSR reporting and PSUR obligations.<\/li>\n<li><strong>Variations:<\/strong> changes to the reference dossier do not automatically transfer. Each MAH must submit its own variations, ideally in parallel, to keep the products aligned.<\/li>\n<li><strong>Product information:<\/strong> safety updates to the SmPC and package leaflet must be implemented on both products within the required timelines.<\/li>\n<li><strong>Supply and quality:<\/strong> batch release, GMP and GDP responsibilities need to be clearly allocated where manufacturing is shared.<\/li>\n<\/ul>\n<p>This makes the contract between the partners as important as the dossier. Consent scope, access to the evolving dossier, coordination of variations, safety data exchange and termination arrangements should all be written down before submission.<\/p>\n\n<h2>How PQRA helps<\/h2>\n<p>PQRA supports originators, licensees and co-marketing partners through every stage of the informed consent route: assessing whether Article 10c or a duplicate is the right legal basis, preparing Module 1 and the consent documentation, managing submissions to EOF and through MRP\/DCP, and setting up the pharmacovigilance, safety data exchange and variation coordination that keep two authorisations in step for their whole lifecycle.<\/p>\n<p><a href=\"\/el\/contact\/\"><strong>Planning a co-marketing launch or second brand in Greece? Talk to PQRA about the fastest compliant route to market.<\/strong><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Not every new marketing authorisation needs a new dossier. Under Article 10c of Directive 2001\/83\/EC, a company can obtain its own authorisation for a medicine that is already approved, relying entirely on the original holder&#8217;s data with that holder&#8217;s written consent. For co-marketing partnerships, second brands and licensing deals in Greece and across the EU, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1420,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1419","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU - PQRA\" \/>\n<meta property=\"og:description\" content=\"Not every new marketing authorisation needs a new dossier. Under Article 10c of Directive 2001\/83\/EC, a company can obtain its own authorisation for a medicine that is already approved, relying entirely on the original holder&#8217;s data with that holder&#8217;s written consent. For co-marketing partnerships, second brands and licensing deals in Greece and across the EU, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-20T05:04:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-20T05:04:17+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU\",\"datePublished\":\"2026-11-20T05:04:01+00:00\",\"dateModified\":\"2026-11-20T05:04:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/\"},\"wordCount\":660,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-informed-consent-article-10c.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/\",\"name\":\"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-informed-consent-article-10c.png\",\"datePublished\":\"2026-11-20T05:04:01+00:00\",\"dateModified\":\"2026-11-20T05:04:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-informed-consent-article-10c.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-informed-consent-article-10c.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/","og_locale":"el_GR","og_type":"article","og_title":"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU - PQRA","og_description":"Not every new marketing authorisation needs a new dossier. Under Article 10c of Directive 2001\/83\/EC, a company can obtain its own authorisation for a medicine that is already approved, relying entirely on the original holder&#8217;s data with that holder&#8217;s written consent. For co-marketing partnerships, second brands and licensing deals in Greece and across the EU, [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/","og_site_name":"PQRA","article_published_time":"2026-11-20T05:04:01+00:00","article_modified_time":"2026-11-20T05:04:17+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"3 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU","datePublished":"2026-11-20T05:04:01+00:00","dateModified":"2026-11-20T05:04:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/"},"wordCount":660,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-informed-consent-article-10c.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/","url":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/","name":"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-informed-consent-article-10c.png","datePublished":"2026-11-20T05:04:01+00:00","dateModified":"2026-11-20T05:04:17+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-informed-consent-article-10c.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-informed-consent-article-10c.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/informed-consent-applications-and-duplicate-marketing-authorisations-using-article-10c-for-co-marketing-in-the-eu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1419"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1419\/revisions"}],"predecessor-version":[{"id":1421,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1419\/revisions\/1421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1420"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}